Results 131 to 140 of about 3,116,614 (307)

Supplementary Table 1 from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis [PDF]

, 2023
Alessandro Prete, Agnes S. Lo, Peter M. Sadow, Swati S. Bhasin, Zeus A. Antonello, Danica M. Vodopivec, Soumya Ullas, Jennifer N. Sims, John G. Clohessy, Ann M. Dvořàk, Tracey Sciuto, Manoj Bhasin, Joanne E. Murphy-Ullrich, Jack Lawler, S. Ananth Karumanchi, Carmelo Nucera   +15 more
openalex   +1 more source

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. [PDF]

, 2008
The clinical success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles. It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of ...
Aizenstein, Brian, Apsel, Beth, Blair, Jimmy A, Feldman, Morri E, Gonzalez, Beatriz, Hoffman, Randy, Knight, Zachary A, Nazif, Tamim M, Shokat, Kevan M, Williams, Roger L   +9 more
core  

PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma

Cell Death Discovery, 2023
Sorafenib is the first FDA-approved first-line targeted drug for advanced HCC. However, resistance to sorafenib is frequently observed in clinical practice, and the molecular mechanism remains largely unknown.
Yu Sha, Mingang Pan, Yunmeng Chen, Liangjun Qiao, Hengyu Zhou, Dina Liu, Wen‐lu Zhang, Kai Wang, Lu-yi Huang, N. Tang, Jianguo Qiu, Ai-long Huang, J. Xia   +12 more
semanticscholar   +1 more source

Fibrates Inhibit PLTP‐induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs

Advanced Science, EarlyView.
Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang, Yaning Li, Jianxun Cai, Lisi Luo, Pengfei Yang, Yutong Chen, Jiancong Zhou, Yan Zeng, Jiaping Yu, Weiyu Zhang, Wenzheng Pang, Yufang Li, Chunhua Wen, Jian Li, Linjuan Zeng   +14 more
wiley   +1 more source

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. [PDF]

, 2017
Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML).
Arbiser, Jack L, Bradley, Heath L, Bunting, Kevin D, Kapur, Reuben, Metts, Jonathan, Shah, Neil P, Wang, Zhengqi   +6 more
core   +1 more source

PDIA3 Inhibition Facilitates Sensitivity of IKE‐Induced Ferroptosis via STAT3/LCN2 Axis to Improve Glioblastoma Therapy

Advanced Science, EarlyView.
In this manuscript, protein disulfide isomerase A3 (PDIA3) is identified as a key factor mediating the susceptibility of ferroptosis in GBM. Inhibition of PDIA3 enhances IKE or cystine starvation‐induced ferroptosis in GBM cells by resulting in the accumulation of lipid peroxidation and a reduction in GSH level.
Jie Zhang, Wei Wang, Xin Liu, Peifen Lu, Xinjing Liu, Qiucheng Nie, Siyuan Xin, Hong Li, Donglin Yu, Xinyue Zhang, Kailong Li, Xiaomin Han, Shuping Zhang, Wei Chong, Lili Sun, Wei Li, Tao Xin, Jin Jiao, Qiang Ma, Yiju Wei   +19 more
wiley   +1 more source

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]

, 2017
Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W, Duan, Zhijian, Ho, Pui Yan, Jian, Chao, Lam, Kit S, Lara, Primo N, Qiu, Jing-Xin, Tu, Mei-Juan, Wun, Theodore, Yu, Ai-Ming, Yu, Ai-Xi, Zhang, Qianyu   +11 more
core   +1 more source

RBM38 Reverses Sorafenib Resistance in Hepatocellular Carcinoma Cells by Combining and Promoting lncRNA-GAS5

Cancers, 2023
Simple Summary Hepatocellular carcinoma (HCC) represents the fourth leading cause of cancer-related death in the world. Sorafenib, a first-line chemotherapeutic drug that inhibits cell growth and angiogenesis, has become the standard therapy for ...
Xing Gao, Cheng Lu, Ziyu Liu, Yan Lin, Julu Huang, Lu Lu, Shuanghang Li, Xi Huang, Minchao Tang, Shi-Qing Huang, Ziqin He, Xiaomin She, R. Liang, J. Ye   +13 more
semanticscholar   +1 more source

Autophagy inhibition overcomes sorafenib resistance in S45F‐mutated desmoid tumors [PDF]

Cancer, 2019
Background Desmoid tumors (DTs) are rare and understudied fibroblastic lesions that are frequently recurrent and locally invasive. DT patients often experience chronic pain, organ dysfunction, decrease in quality of life, and even death. Methods
Danielle Braggio, David Koller, Feng Jin, Nanda Siva, Abeba Zewdu, Gonzalo Lopez, Kara Batte, Lucia Casadei, Meng Welliver, Anne M. Strohecker, Dina Lev, Raphael E. Pollock   +11 more
openaire   +2 more sources

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, Yongling Ji, Keying Chen, Zhengbo Song, Runzhe Chen, Xuan Li, Qi Zhao, Qixun Chen, Ming Chen   +12 more
wiley   +1 more source